About Tubulin alpha-1A chain
Tubulin alpha-1A chain (TUBA1A) is a protein
from Homo sapiens identified by UniProt accession
Q71U36, 451 residues long.
MolForge cross-references it against 0 known binders and
263 disease associations.
Target properties
| Protein name | Tubulin alpha-1A chain |
| UniProt accession | Q71U36 |
| Gene | TUBA1A |
| Organism | Homo sapiens |
| Length | 451 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (263)
Diseases linked to this target (Open Targets).
- lissencephaly due to TUBA1A mutation · score 0.82
- tubulinopathy · score 0.66
- tubulinopathy-associated dysgyria · score 0.61
- lissencephaly type 3 · score 0.61
- Lissencephaly · score 0.58
- genetic disorder · score 0.54
- congenital fibrosis of extraocular muscles · score 0.53
- neurodegenerative disease · score 0.53
- Intellectual disability · score 0.51
- viral disease · score 0.46
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q71U36-F1 | alphafold | PREDICTED | 91.12 | — |
Amino-acid sequence (451 residues)
MRECISIHVG QAGVQIGNAC WELYCLEHGI QPDGQMPSDK TIGGGDDSFN TFFSETGAGK HVPRAVFVDL EPTVIDEVRT GTYRQLFHPE QLITGKEDAA NNYARGHYTI GKEIIDLVLD RIRKLADQCT GLQGFLVFHS FGGGTGSGFT SLLMERLSVD YGKKSKLEFS IYPAPQVSTA VVEPYNSILT THTTLEHSDC AFMVDNEAIY DICRRNLDIE RPTYTNLNRL IGQIVSSITA SLRFDGALNV DLTEFQTNLV PYPRIHFPLA TYAPVISAEK AYHEQLSVAE ITNACFEPAN QMVKCDPRHG KYMACCLLYR GDVVPKDVNA AIATIKTKRT IQFVDWCPTG FKVGINYQPP TVVPGGDLAK VQRAVCMLSN TTAIAEAWAR LDHKFDLMYA KRAFVHWYVG EGMEEGEFSE AREDMAALEK DYEEVGVDSV EGEGEEEGEE Y
Explore Tubulin alpha-1A chain with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets